 This study is designed to evaluate the additional efficacy and safety of olmesartan medoxomilhydrochlorothiazide in the treatment of Chinese patients with mild to moderate essential hypertension, who fail to attain the blood pressure goals with olmesartan medoxomil monotherapy 